Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07214363) titled 'The Safety and Efficacy of Irreversible Electroporation for the Treatment of Perivascular Liver Cancers' on Oct. 1.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: National Taiwan University Hospital
Condition:
Liver Cancer
Ablation Techniques
Radiology
Intervention:
Device: Irreversible Electroporation Ablation Generator
Recruitment Status: Not recruiting
Phase: N/A
Date of First Enrollment: October 1, 2023
Target Sample Size: 20
Countries of Recruitment:
Taiwan
To know more...